Plasma essential fatty acid on hospital admission is a marker of COVID-19 disease severity.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 11 2023
03 11 2023
Historique:
received:
15
06
2023
accepted:
30
10
2023
medline:
6
11
2023
pubmed:
4
11
2023
entrez:
4
11
2023
Statut:
epublish
Résumé
It is important for allocation of resources to predict those COVID patients at high risk of dying or organ failure. Early signals to initiate cellular events of host immunity can be derived from essential fatty acid metabolites preceding the cascade of proinflammatory signals. Much research has focused on understanding later proinflammatory responses. We assessed if remodelling of plasma phospholipid content of essential fatty acids by the COVID-19 virus provides early markers for potential death and disease severity. Here we show that, at hospital admission, COVID-19 infected subjects who survive exhibit higher proportions of C20:4n-6 in plasma phospholipids concurrent with marked proinflammatory cytokine elevation in plasma compared to healthy subjects. In contrast, more than half of subjects who die of this virus exhibit very low C18:2n-6 and C20:4n-6 content in plasma phospholipids on hospital admission compared with healthy control subjects. Moreover, in these subjects who die, the low level of primary inflammatory signals indicates limited or aberrant stimulation of host immunity. We conclude that COVID-19 infection results in early fundamental remodelling of essential fatty acid metabolism. In subjects with high mortality, it appears that plasma n-6 fatty acid content is too low to stimulate cellular events of host immunity.
Identifiants
pubmed: 37923927
doi: 10.1038/s41598-023-46247-0
pii: 10.1038/s41598-023-46247-0
pmc: PMC10624896
doi:
Substances chimiques
Fatty Acids, Unsaturated
0
Fatty Acids
0
Phospholipids
0
Fatty Acids, Essential
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18973Subventions
Organisme : CIHR
ID : RES0052607
Pays : Canada
Informations de copyright
© 2023. The Author(s).
Références
Medicina (Kaunas). 2022 Jan 18;58(2):
pubmed: 35208467
J Pediatr Gastroenterol Nutr. 2017 Mar;64(3):446-453
pubmed: 27276431
J Clin Invest. 2021 Oct 1;131(19):
pubmed: 34428181
Viruses. 2019 Jan 16;11(1):
pubmed: 30654597
Acta Paediatr. 1999 Aug;88(8):890-6
pubmed: 10503691
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Mar Drugs. 2019 May 08;17(5):
pubmed: 31072006
J Nutr. 1983 Jun;113(6):1187-94
pubmed: 6343564
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32687484
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Mediators Inflamm. 2020 Dec 2;2020:8829674
pubmed: 33343232
Int J Clin Pract. 2021 Oct;75(10):e14357
pubmed: 33977626
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Front Physiol. 2021 Jul 01;12:668330
pubmed: 34276398
J Immunol. 2005 Jan 15;174(2):589-94
pubmed: 15634873
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
Inflammopharmacology. 2022 Jun;30(3):789-798
pubmed: 35505267
Science. 2020 Nov 6;370(6517):725-730
pubmed: 32958580
Ann Rheum Dis. 2020 Sep;79(9):1253-1254
pubmed: 32345616
Blood Rev. 2021 Mar;46:100743
pubmed: 32829962
J Lipid Res. 2010 Aug;51(8):2325-33
pubmed: 20427696
PLoS Pathog. 2020 Dec 7;16(12):e1009128
pubmed: 33284859
Neuron. 2022 Oct 5;110(19):3186-3205.e7
pubmed: 35961319
Science. 2004 Nov 26;306(5701):1517-9
pubmed: 15567854